Options Recaps, Fresh Ideas

Options Reviews

We issued a couple of fresh options ideas in yesterday morning’s report, concerning SMAR and SFIX, which had both reported quarterly earnings in the premarket. We took interest in the SMAR 12/18 $70-75 Calls and the SFIX Weekly $45-50 Calls. 

We witnessed good intraday performances in both cases, with SMAR outperforming SFIX, but not by a whole lot. Both plays will have provided our readers with plenty of opportunity to get in and out for some nice gains on the day.

Here were the total ranges and possible profits on those contracts: 

SMAR 12/18 $70-75 Calls
$70
: 2.10-6.80 (+136%)
$75: 1.11-3.65 (+219%)
_____

SFIX Weekly $45-50 Calls 
$45: 5.00-7.99 (+136%)
$46: 4.46-7.29 (+219%)
$50: 1.90-4.59 (+222%)


Fresh Options Ideas:

GME Weekly $15.50-14 Puts
ZI 04/16 $45-50 Calls
SPLK Weekly $160 Calls
ROKU Weekly $310-315 Calls 


Extended Watchlist:
CURR, SFOR, NECA, APYP, TLSS, BSSP

CURR Report, Options Ideas

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

Many of our regular readers will be familiar with CURE Pharmaceutical, a company that we profiled in a recent premarket report on November 25th. That morning, CURR shares registered a low of .99, and have made a pretty impressive move in the eight trading sessions since. Yesterday brought a new high of 1.82, which marks an overall increase of 83%

When we initially mentioned it, we looked at CURR as a possible bottom-play, which it certainly turned out to be. We would now classify it as a momentum mover, although as we’ve mentioned previously, there is an interesting backstory as well. 

In our first report, we commented on the interesting proprietary technology the company had for vitamin/supplement delivery via orally-ingested film strips called Nutri-Strips. According to a recent statement from CURE CSO Nancy Duitch (CEO of The Sera Labs) the recent acquisition of The Sera Labs by CURE was primarily about assisting with and expediting the commercialization of Sera’s products that utilize this technology, which is referred to as RAD(Rapid Activation Delivery).

The first variety of oral supplements that CURE has made available via its online retail portal is a sleep aid, and according to the company, consumers can expect between three and six others to hit the storefront in early 2021.

The roll-out and advertising campaigns designed by CURE for the emerging lines have been described by company officials as aggressive. It has been less than six months since the original announcement of the acquisition of The Sera Labs, so we would submit that aggressive is an appropriate characterization.  Speaking of which, CURE has released another PR update this morning, announcing a partnership with a blockbuster movie star which we will share below.


Fresh CURR News:

LOS ANGELES & OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holdings (OTCMKTS: CURR) wholly owned subsidiary, The Sera Labs, Inc., has enlisted Oscar, Golden Globe and Emmy Award-winning Nicole Kidman as the brand’s first-ever strategic business partner and global brand ambassador for their topical products. In addition to being the face of the brand, Kidman will play an integral role in the strategic direction of product development and messaging.

“The partnership with SeraLabs was an easy decision for me,” states Kidman, SeraLabs Strategic Partner and Global Brand Ambassador. “With my injury last year, I experienced the benefit of CBD wellness products firsthand. I believe these products are a vital solution in health and wellness and Nancy and SeraLabs are a company I believe in. Joining them in this partnership is something I am very excited about!” (>>View Full PR)


CURR Video Chart: 

We would suggest our readers take a moment to view the video presentation we’ve prepared for the current CURR chart, which has recently broken through the key resistance areas we highlighted in our previous report.


CURR Video Chart


For All Investor Inquiries on CURR,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com 


Fresh Options Ideas:

We’ve also identified a couple of solid looking potential plays on the big board earnings calendar this morning:

SMAR 12/18 $70-75 Calls
SFIX Weekly $45-50 Calls


Kicking Off a Fresh Trading Week

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

We updated readers on the fresh PR that was posted by PBIO on Friday morning, and today we want to wrap back around to talk about the solid move the stock made last week. We signaled it in our extended watchlist on Wednesday, before sending out a more detailed report on Thursday.

The stock has made some nice gains over that three session span, coming from a low of of 1.5957 Wednesday, and running as high as 2.75 on Friday. That works out to a three-day upswing of 72% which occurred on very high volume relative to the 30-day moving average. In the event of any pullbacks we’d like to see the stock maintain support above its 200DMA at around 2.10.

We definitely want to continue to monitor the situation, and will relay any pertinent updates to our readers as they become available.



JinkoSolar Holdings Co. Ltd. JKS – Fresh Options Idea

The earnings calendar is a little light to kick the week off this morning, but we have identified one possible swing trade target in JKS. We’re going to go out to next month’s expiration and flag the JKS 01/15 $60-65 Calls for observation.


PBIO News, Options Recaps

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

First thing’s first today, we’ve got some fresh news out on PBIO that we wanted to pass along to our readers this morning. We sent out a report on PBIO yesterday that we would suggest you take a minute to go over now.

Today we are seeing the company release important info on the launch of its FDA-registered cannabis-enhanced, immune boosting prebiotic with proposed acquisition partner, Cannaworx

SOUTH EASTON, Mass., Dec. 4, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCMKTS: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its proposed acquisition partner Cannaworx, Inc. has set December 2020 as the commercial launch date for its patented immune booster supplement: ImmunaZin™.  Cannaworx believes that post-launch, this product will be one of very few OTC (over the counter), FDA registered, hemp seed oil-enhanced supplements with an immune booster claim. (>>View Full PR via OTCMARKETS)


Successful Options Review

We also formulated some fresh options ideas for yesterday’s session in our premarket report, and found some solid success in the case of the CRWD and SPLK chains.

Here are the total ranges and possible profits that could have been seized: 

CRWD Weekly $155-162.50 Calls
$155: 3.92-11.25 (+187%)
$157.50: 3.00-8.87 (+197%)
$160: 2.14-7.75 (+262%)
$162.50: 1.63-5.75 (+253%)
_____

SPLK Weekly $170-160 Puts 
$170: 5.71-13.50 (+136%)
$165: 2.80-8.93 (+219%)
$160: 1.12-5.31 (+222%)
_____

Fresh Options Ideas:
DOCU Weekly $242.50-247.50 Calls 
ULTA Weekly $275-282.50 Calls 

PBIO Report, Options Ideas

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

Pressure BioSciences is a company we’ve had on our watchlist for quite some time, with our first mention of the stock coming in the summer of 2019. We’re taking a renewed look at it now for a number of reasons, not least of which being the long term pattern of the chart.

If you glance at the three-year snapshot below (via OTCMARKETS.COM), a clear pattern can be easily spotted. The stock has an undeniable recorded history of consolidating in the winter months,only to spring back with vigor in the early portions of each New Year.

On its own, that interesting technical tendency would be enough to catch our attention, but Pressure BioSciences also seems to be planning for a big year of developments in 2021 as mentioned in the company’s Q3 Business Update released just a couple of weeks ago. According to the company, it expects the upcoming release of its Ultra Shear Technology™ in mid-2021 to drive notable growth and progress toward becoming profitable.

That only scratches the surface of PBIO’s products, projects and partnerships, which were expounded upon in the aforementioned Quarterly Update (>>View Now on OTCMARKETS.COM) Stay tuned for any further updates which we’ll be sure to pass along as expediently as possible!
_____

We also suggest our readers take a moment to view a real-time look at the short term PBIO chart . The stock is coming off of support at the 50DMA of 1,60, and it breached the 200DMA yesterday, closing just below it. If PBIO can break the 200DMA at 2.08 and hold above, our next key resistance points come at 2.50, 3.00, and 4.00-4.50. 


View PBIO Video Chart
______

For All Investor Inquiries on PBIO,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com 


SPDR S&P500 (ETF) SPY – Options Review

We also wanted to quickly highlight the SPY 12/02 $365-366 Calls which we signaled for a last minute idea in yesterday morning’s premarket report. We saw some pretty good intraday gains out of those targets.

SPY 12/02 $365-366 Calls
$365: .59-2.19 (+271%)
$366: .28-1.32 (+371%)
_____

Fresh Options Ideas:
SPLK Weekly $170-160 Puts
CRWD Weekly $155-162.50 Calls
SIG Weekly $30.50-32 Calls 


Get Our FREE Daily Reports!